Interaction of estrogen receptor β5 and interleukin 6 receptor in the progression of non–small cell lung cancer
Autor: | Shufang Xu, Xiaoling Wu, Hexiao Tang, Li Zhang, Li Yu, Lecai Xiong, Ding Long, Junhui Yang, Minglin Zhu, Yuquan Bai, Yanhong Wei, Jinping Zhao |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
business.industry Cell growth Cell Estrogen receptor non-small cell lung cancer (NSCLC) Cell Biology Cell cycle medicine.disease Biochemistry 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Interleukin-6 receptor medicine Cancer research Lung cancer business Molecular Biology Estrogen receptor beta |
Zdroj: | Journal of Cellular Biochemistry. 120:2028-2038 |
ISSN: | 1097-4644 0730-2312 |
DOI: | 10.1002/jcb.27510 |
Popis: | Numerous studies have shown that the estrogen receptor beta (ERβ) and interleukin 6 receptor (IL-6R) had interaction in many tumors, including lung cancer. Previous studies found that ERβ5 exhibits a different biological function compared with the other subtypes of ERβ. Therefore, this study mainly explores the interaction between ERβ5 and IL-6R in the progression of lung cancer. We found that the expression of ERβ5, IL-6 and glycoprotein 130 (GP130) were significantly increased (P < 0.001) and the 5-year survival rate with the co-expression of ERβ5 and GP130 is significantly lower (P = 0.0315) in non-small cell lung cancer (NSCLC) patients. The cell proliferation, invasion, and cell cycle were markedly increased, and the cell apoptotic was markedly inhibited with the concurrent action of ERβ5 and IL-6 in A549 cells (P < 0.05). In addition, the expression of ERβ5, GP130, p-AKT, and p-44/42 MAPK was also significantly increased in A549 cells (P < 0.05). These results indicate that ERβ5 and GP130 can synergistically promote the progression of NSCLC and maybe combined as an independent prognostic factor in patients. In addition, these results also provide a theoretical basis for the combined targeting therapy of ERβ5 and GP130 in NSCLC. |
Databáze: | OpenAIRE |
Externí odkaz: |